About us

More about the founders of Macrobian-Biotech


Be at the forefront of clinical trial ready compound development vivifying novel treatments of neurological and neuropsychiatric diseases


Read the latest updates from Macrobian-Biotech

Who are we

Macrobian-Biotech was founded in May 2017 by Dr. Lars van der Heide and Prof. dr. Marten Smidt. Its primary goal is to perform pre-clinical research that leads to noval treatments for disorders that affect the midbrain dopamine system. The company is currently housed at the Amsterdam Science Park, the heart of academic excellence in the Netherlands.

State Of The Art

Macrobian-Biotech utilizes state of the art technology and is at the very front of scientific breakthroughs. The company’s step-by-step mechanistic approach to unravel molecular components of dopamine neurons has lead to the identification of novel compounds that are able to modulate dopamine production specifically in midbrain dopamine neurons.

The constant perfectioning and upgrading of such compounds is the current core business of Macrobian-Biotech. Its perspective is to deliver a fully tested and safe compound to be verified in clinical trials.